{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:57:49Z","timestamp":1790906269456,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Not Affiliated"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajo.2025.06.010","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T11:27:14Z","timestamp":1749554834000},"page":"570-579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Treatment of Retinal\/Choroidal Vascular Diseases by Sustained Delivery of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-452X","authenticated-orcid":false,"given":"Dilsher S.","family":"Dhoot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajo.2025.06.010_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","article-title":"Vascular endothelial growth factors and angiogenesis in eye disease","volume":"22","author":"Witmer","year":"2003","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.ajo.2025.06.010_bib0002","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/2474126420971982","article-title":"A history of anti-VEGF inhibitors in the ophthalmic literature: a bibliographic review","volume":"5","author":"Whitescarver","year":"2021","journal-title":"J Vitreoretin Dis"},{"issue":"1","key":"10.1016\/j.ajo.2025.06.010_bib0003","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2025.06.010_bib0004","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic retinopathy preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2025.06.010_bib0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.06.010_bib0006","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.2147\/OPTH.S185052","article-title":"The burden of neovascular age-related macular degeneration: a patient's perspective","volume":"12","author":"Spooner","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.06.010_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000502747","article-title":"Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset","volume":"243","author":"Mon\u00e9s","year":"2020","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ajo.2025.06.010_bib0008","article-title":"Ranibizumab port delivery system in neovascular age-related macular degeneration","volume":"14","author":"Chandrasekaran","year":"2022","journal-title":"Ther Adv Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.06.010_bib0009","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41433-021-01842-1","article-title":"Review of gene therapies for age-related macular degeneration","volume":"36","author":"Khanani","year":"2022","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.ajo.2025.06.010_bib0010","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.ajo.2025.06.010_bib0011","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.3390\/ijms21228529","article-title":"Tyrosine kinase receptors in oncology","volume":"21","author":"Esteban-Villarrubia","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ajo.2025.06.010_bib0012","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/08820538.2022.2152706","article-title":"Molecular mediators and regulators of retinal angiogenesis","volume":"38","author":"Vishwakarma","year":"2023","journal-title":"Semin Ophthalmol"},{"issue":"9807","key":"10.1016\/j.ajo.2025.06.010_bib0013","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ajo.2025.06.010_bib0014","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ajo.2025.06.010_bib0015","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ajo.2025.06.010_bib0016","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10238-007-0145-8","article-title":"Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib","volume":"7","author":"Porta","year":"2007","journal-title":"Clin Exp Med"},{"issue":"1","key":"10.1016\/j.ajo.2025.06.010_bib0017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000055638","article-title":"Effect of particle size of polymeric nanospheres on intravitreal kinetics","volume":"33","author":"Sakurai","year":"2001","journal-title":"Ophthalmic Res"},{"issue":"1","key":"10.1016\/j.ajo.2025.06.010_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/IIO.0000000000000551","article-title":"Tyrosine kinase inhibitors: the next chapter in reducing treatment burden for exudative retinal diseases?","volume":"65","author":"Ravichandran","year":"2025","journal-title":"Int Ophthalmol Clin"},{"issue":"3","key":"10.1016\/j.ajo.2025.06.010_bib0019","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14728214.2023.2259790","article-title":"A review of emerging tyrosine kinase inhibitors as durable treatment of neovascular age-related macular degeneration","volume":"28","author":"Das","year":"2023","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.ajo.2025.06.010_bib0020","unstructured":"CLN-0046: treatment of AMD subjects with OTX-TKI. ClinicalTrials.gov identifier: NCT03630315. Updated July 10, 2024. Accessed August 4, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0021","series-title":"American Academy of Ophthalmology","article-title":"Australia-based phase 1 trial of a novel, hydrogel-based, intravitreal Axitinib implant for the treatment of neovascular age-related macular degeneration","author":"Moshfeghi","year":"2022"},{"key":"10.1016\/j.ajo.2025.06.010_bib0022","series-title":"Retinal World Congress","article-title":"Week 52 safety and efficacy data from the US phase 1 clinical trial of sustained-release axitinib hydrogel implant (OTX-TKI) for neovascular age-related macular degeneration","author":"Dhoot","year":"2024"},{"key":"10.1016\/j.ajo.2025.06.010_bib0023","unstructured":"Study evaluating the treatment of OTX-TKI for subjects with neovascular age-related macular degeneration. ClinicalTrials.gov identifier: NCT04989699. Updated January 26, 2024. Accessed August 4, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0024","series-title":"Interim safety and efficacy results from the phase 1 HELIOS Trial of sustained-release axitinib implant (OTX-TKI) for NPDR","author":"Dhoot","year":"2024"},{"key":"10.1016\/j.ajo.2025.06.010_bib0025","unstructured":"Study to evaluate the safety, tolerability, and efficacy of OTX-TKI in subjects with moderately severe to severe non-proliferative diabetic retinopathy. ClinicalTrials.gov identifier: NCT05695417. Updated December 8, 2023. Accessed August 4, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0026","unstructured":"Ocular therapeutix highlights exceptional AXPAXLI SOL-1 enrollment and plans for repeat dosing study (SOL-R) in wet AMD at Investor Day, along with positive 48-week data from HELIOS NPDR Study. News Release. June 13, 2024. Accessed August 4, 2024. https:\/\/investors.ocutx.com\/news-releases\/news-release-details\/ocular-therapeutixtm-highlights-exceptional-axpaxlitm-sol-1."},{"key":"10.1016\/j.ajo.2025.06.010_bib0027","unstructured":"Study to evaluate the efficacy and safety of intravitreal OTX-TKI (Ocular Therapeutix) (axitinib implant) in subjects with neovascular age-related macular degeneration. ClinicalTrials.gov identifier: NCT06223958. Updated July 5, 2024. Accessed August 4, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0028","unstructured":"Ocular Therapeutix announces first patients enrolled in phase 3 SOL-R Wet AMD Study. News Release. July 30, 2024. Accessed August 4, 2024. https:\/\/investors.ocutx.com\/news-releases\/news-release-details\/ocular-therapeutixtm-announces-first-patients-enrolled-phase-3."},{"key":"10.1016\/j.ajo.2025.06.010_bib0029","unstructured":"Study to evaluate the efficacy and safety of intravitreal OTX-TKI (axitinib implant) in subjects with neovascular age-related macular degeneration. ClinicalTrials.gov identifier: NCT06495918. Updated July 24, 2024. Accessed August 4, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0031","unstructured":"Safety and tolerability study of suprachoroidal injection of CLS-AX following anti-VEGF therapy in neovascular AMD (OASIS). ClinicalTrials.gov identifier: NCT04626128. Updated September 18, 2023. Accessed August 4, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0032","unstructured":"Extension study to evaluate the long-term outcomes of subjects in the CLS-AX CLS1002-101 Study. ClinicalTrials.gov identifier: NCT05131646. Updated March 4, 2024. Accessed August 4, 2024."},{"issue":"1","key":"10.1016\/j.ajo.2025.06.010_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100586","article-title":"Safety and tolerability of suprachoroidal axitinib, CLS-AX, for neovascular AMD; phase 1\/2a open-label, dose-escalation trial","volume":"5","author":"Barakat","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.ajo.2025.06.010_bib0035","unstructured":"Study to evaluate suprachoroidally administered CLS-AX in the treatment of neovascular age-related macular degeneration (ODYSSEY). ClinicalTrials.gov identifier: NCT05891548. Updated November 11, 2023. Accessed August 4, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0036","unstructured":"Clearside Biomedical announces positive topline results from ODYSSEY phase 2b trial of suprachoroidal CLS-AX in wet AMD achieving all primary and secondary outcomes. News release. October 9, 2024. Accessed May 26, 2025. https:\/\/ir.clearsidebio.com\/news-releases\/news-release-details\/clearside-biomedical-announces-positive-topline-results-odyssey."},{"key":"10.1016\/j.ajo.2025.06.010_bib0037","unstructured":"Study of AR-14034 in participants with neovascular age-related macular degeneration (nAMD) (NOVA-1). ClinicalTrials.gov identifier: NCT05769153. Updated May 29, 2024. Accessed August 4, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0038","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jconrel.2021.05.035","article-title":"Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration","volume":"335","author":"Kambhampati","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.ajo.2025.06.010_bib0039","unstructured":"A study to evaluate the safety, tolerability, and pharmacokinetics of D-4517.2 after subcutaneous administration in healthy participants. ClinicalTrials.gov identifier: NCT05105607. Updated September 21, 2022. Accessed August 4, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0040","unstructured":"Ashvattha Therapeutics announces first patient dosed via subcutaneous administration of anti-angiogenic therapeutic D-4517.2 for wet AMD and DME in phase 2 chronic dosing study. News release. November 1, 2023. July 28, 2024; Available from: https:\/\/avttx.com\/ashvattha-therapeutics-announces-first-patient-dosed-via-subcutan0eous-administration-of-anti-angiogenic-therapeutic-d-4517-2-for-wet-amd-and-dme-in-phase-2-chronic-dosing-study\/."},{"key":"10.1016\/j.ajo.2025.06.010_bib0041","unstructured":"A study to evaluate the safety, tolerability and pharmacokinetics of D-4517.2 after subcutaneous administration in subjects with neovascular (Wet) age-related macular degeneration (AMD) or subjects with diabetic macular edema (DME). ClinicalTrials.gov identifier: NCT05387837. Updated February 13, 2023. Accessed July 28, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0042","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2147\/DDDT.S295223","article-title":"Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration","volume":"15","author":"Hussain","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ajo.2025.06.010_bib0043","unstructured":"A depot formulation of sunitinib malate (GB-102) in subjects with neovascular (wet) age-related macular degeneration. ClinicalTrials.gov identifier: NCT03249740. Updated December 20, 2019. Accessed August 4, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0044","unstructured":"A depot formulation of sunitinib malate (GB-102) compared to aflibercept in subjects with wet AMD (ALTISSIMO). ClinicalTrials.gov identifier: NCT03953079. Updated January 19, 2022. Accessed August 4, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0045","unstructured":"Sheth V. Intravitreal sunitinib malate depot (GB-102): durability and safety in wet age-related macular degeneration (ALTISSIMO, phase 2B) Presented at: American Academy of Ophthalmology; November 13, 2021; New Orleans, LA."},{"issue":"5","key":"10.1016\/j.ajo.2025.06.010_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100527","article-title":"Phase I DAVIO Trial: EYP-1901 bioerodible, sustained-delivery vorolanib insert in patients with wet age-related macular degeneration","volume":"4","author":"Patel","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.ajo.2025.06.010_bib0047","unstructured":"Wykoff C. THE DAVIO 2 TRIAL: topline data from a phase 2, multicenter study of a single injection of EYP-1901 (Vorolanib in the Durasert E\u2122 technology) vs aflibercept for previously treated wet age-related macular degeneration, in angiogenesis. 2024: Virtual."},{"key":"10.1016\/j.ajo.2025.06.010_bib0048","series-title":"Macula Society Annual Meeting","article-title":"The Davio 2 trial: a phase 2 multicenter study of a single injection of EYP-1901 vs aflibercept for wet age-related macular degeneration","author":"Singh","year":"2024"},{"key":"10.1016\/j.ajo.2025.06.010_bib0049","unstructured":"EyePoint Pharmaceuticals announces topline data from the phase 2 PAVIA Trial of DURAVYU in non-proliferative diabetic retinopathy. News release. May 6, 2024. Accessed August 10, 2024. https:\/\/investors.eyepointpharma.com\/news-releases\/news-release-details\/eyepoint-pharmaceuticals-announces-topline-data-phase-2-pavia."},{"key":"10.1016\/j.ajo.2025.06.010_bib0050","unstructured":"Study of EYP-1901 in patients with nonproliferative diabetic retinopathy (NPDR). ClinicalTrials.gov identifier: NCT05383209. Updated February 12, 2024. Accessed August 12, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0051","unstructured":"Study of EYP-1901 in patients with diabetic macular edema (DME) (VERONA). ClinicalTrials.gov identifier: NCT06099184. Updated December 5, 2023. Accessed August 18, 2024."},{"key":"10.1016\/j.ajo.2025.06.010_bib0053","unstructured":"EyePoint Pharmaceuticals announces positive interim 16-week data for ongoing phase 2 VERONA clinical trial of DURAVYU\u2122 for diabetic macular edema. News release. October 28, 2024. Accessed November 5, 2024. https:\/\/investors.eyepointpharma.com\/news-releases\/news-release-details\/eyepoint-pharmaceuticals-announces-positive-interim-16-week-data."},{"issue":"5","key":"10.1016\/j.ajo.2025.06.010_bib0055","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s10637-021-01093-7","article-title":"Vorolanib (X-82), an oral anti-VEGFR\/PDGFR\/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study","volume":"39","author":"Pedersen","year":"2021","journal-title":"Invest New Drugs"},{"issue":"7","key":"10.1016\/j.ajo.2025.06.010_bib0056","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/jamaophthalmol.2019.0861","article-title":"Oral tyrosine kinase inhibitors for neovascular age-related macular degeneration","volume":"137","author":"Jackson","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.06.010_bib0057","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bjophthalmol-2020-316511","article-title":"APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration","volume":"105","author":"Cohen","year":"2021","journal-title":"Br J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500296X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500296X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T13:34:22Z","timestamp":1754919262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293942500296X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":53,"alternative-id":["S000293942500296X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.06.010","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Retinal\/Choroidal Vascular Diseases by Sustained Delivery of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}